**Original Article**

**Effects of the interaction of diabetes and iron supplementation on hepatic and pancreatic tissues, oxidative stress markers, and liver peroxisome proliferator-activated receptor-\(\alpha\) expression**

Maiisa Silva,¹,⁺ Larissa de Freitas Bonomo,¹ Riva de Paula Oliveira,¹,⁴ Wanderson Geraldo de Lima,¹,² Marcelo Eustáquio Silva²,³ and Maria Lucia Pedrosa¹,²

¹Núcleo de Pesquisas em Ciências Biológicas, Universidade Federal de Ouro Preto, 35400-000, Ouro Preto, Minas Gerais, Brazil
²Departamento de Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
³Departamento de Alimentos, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
⁴Departamento de biodiversidade, Evolução e Meio Ambiente Universidade Federal de Ouro Preto, 35400-000, Ouro Preto, Minas Gerais, Brazil

(Received 2 November, 2010; Accepted 31 December, 2010; Published online 4 June, 2011)

This study evaluated the effects of the interaction of diabetes and a carbonyl iron supplemented on hepatic and pancreatic tissues, oxidative stress markers and liver peroxisome proliferator-activated receptor-\(\alpha\) expressions. Hamsters were divided: Control which received a standard AIN 93 diet; Control Iron, composed of control animals that received a diet with 0.83% carbonyl iron; Diabetic, composed of animals that received a injection of streptozotocin (50 mg/kg, intraperitoneal) on day 35; and Diabetic Iron composed of streptozotocin treated animals that received a diet supplemented with carbonyl iron. Diabetes increased the glucose level and reduced triglycerides. Diabetic Iron group showed higher levels of glucose and serum triglycerides as compared to the Diabetic group. Diabetes decreased mRNA levels of peroxisome proliferator-activated receptor-\(\alpha\). Iron attenuated the diabetes induced down regulation of peroxisome proliferator-activated receptor-\(\alpha\) mRNA. Moreover, diabetes increased carbonyl protein and decreased glutathione levels and catalase activity, while iron attenuated the increase in levels of carbonyl protein and attenuated the decrease in those of glutathione level and catalase activity. Histological analysis shows that supplementation iron caused an increase in the size of the islets in Control Iron. The results show that iron does not aggravate liver oxidant/antioxidant status and peroxisome proliferator-activated receptor-\(\alpha\) expression in diabetic hamsters.

**Key Words:** carbonyl iron, streptozotocin, oxidative stress, hamsters, PPAR-\(\alpha\)

Diabetic mellitus, a chronic metabolic disorder, is one of the most important health problems in the world, especially in developing countries. It is characterized by imperfection in insulin secretion and insulin receptor or post receptor events with derangement in carbohydrate, protein and lipid metabolism and results in chronic hyperglycemia.¹ Chronic hyperglycemia, promotes glucotoxicity, and has negative impacts on various organs and tissues, such as pancreas, liver, kidneys, muscles, etc. Glucoxicity eventually leads to progressive β-cell dysfunction, impaired insulin gene transcription and permanent β-cell loss due to apoptosis, ensuing in a vicious cycle with exasperation of the hyperglycemia.² Indeed, hyperglycemia is contemplated to generate reactive oxygen species through diverse pathways, such as mutilation of the redox equilibrium, augmentation of advanced glycation products, activation of protein kinase C or overproduction of mitochondrial superoxides that eventually leading to oxidative stress in a variety of tissues.³ The vulnerability of each tissue to oxidative stress can vary depending upon their expressed antioxidant enzymes. In addition to the pancreatic β-cells, supraphysiological glucose is notorious to provoke oxidative stress in hepatocytes which can cause hepatic tissue damages.⁴,⁵ Dietary components can modify the redox status of an organism and appear as an important factor in controlling diabetes and its complications. Nutrients such as iron have a dual role, with the ability to increase or decrease the organism’s redox capacity. Iron, acting as a cofactor for many proteins, including antioxidant enzymes, is essential for cellular metabolism and aerobic respiration. However, in high concentrations it can lead to cellular toxicity and oxidative damage of cellular components due to its role in the formation of free radicals.⁶,⁷

Association between excessive systemic iron and diabetes was suggested by the observation that the incidence of diabetes is increased in classical hereditary hemochromatosis,⁸ in which there is a large increase in iron pools. Epidemiological data show a positive correlation between body iron pools and development of glucose intolerance seen in both diabetes type 2⁹–¹¹ and gestational diabetes.¹² Recently, have been demonstrated, in a mouse model of hereditary hemochromatosis, that glucose uptake is increase in skeletal muscle but glucose oxidation is decreased and the ratio of fatty acid to glucose oxidation is increased, that may to contribute to the risk of diabetes with excessive tissue iron.¹³ Together, these observations suggest that there is a close relationship between iron and diabetes pathophysiology. However, not much data exist regarding this relationship in experimental models. Such models would allow better understanding of the mechanisms involved in this interaction and could contribute to a better control of diabetes and to a reduction of its complications when associated to iron supplementation.

To expand knowledge in between diabetes and iron, we sought to describe the effect of iron and diabetes on oxidative stress, liver histology, and lipid homeostase by studying the effects on...
peroxisome proliferator-activated receptor-α (PPAR-α) mRNA in liver of hamsters with a diet supplemented with carbonyl iron, an iron for oral use. A growing body of evidence supports the role of PPAR-α in the development of liver disease and as a putative target for the treatment of steatohepatitis. Disabling the PPAR-α gene is known to increase hepatic triglyceride accumulation, especially under conditions of fasting. Pharmacological PPAR-α activation has been shown to lower hepatic triglyceride levels and effectively attenuate steatohepatitis. Furthermore, diabetes can modulate PPARs through increased inflammatory cytokines and oxidative stress in the heart. Thus it is possible to suppose that the interaction between iron and diabetes might modulate the PPAR-α expression in the liver and, as a consequence, the lipid homeostasis.

We also studied histologic characteristics of pancreas sections. This study allowed us to analyze possible iron effects without excessive iron overload by using the hamster as a model, because this animal has a lipoprotein profile similar to that of humans. This allowed us to establish parallels between the alterations seen here and those known to occur in humans, making this a useful model to unravel the mechanisms involved in this relationship. This relationship is especially relevant in developing countries, which have an increasing incidence of diabetes as well as iron deficiency anemia and, therefore, where an indiscriminate iron supplementation occurs.

Materials and Methods

Animals and experimental design. Female Golden Syrian hamsters, weighing approximately 100 g, were obtained from the School of Nutrition of the Federal University of Ouro Preto and kept in collective cages in rooms with controlled temperature and humidity and with 12-h light and dark cycles. Hamsters received food and water ad libitum. Experiments were conducted according to the principles defined by the Brazilian College of Animal Experimentation. Animal procedures were approved by the Ethics Committee of the Federal University of Ouro Preto. Hamsters were divided into four groups of eight animals each: normal, diabetic (DI), diabetic group (D), and control (C) groups received the standard AIN-93 diet. Control Iron group (CI) received the diet supplemented with 0.83% carbonyl iron according to Dabbagh et al. Diabetic group (D) received an injection of streptozotocin (STZ) at 50 mg/kg, intraperitoneal, according to Iancu et al., on experimental day 35 and was kept on the standard diet. Diabetic Iron (DI) received the STZ injection and was kept on the standard diet supplemented with 0.83% carbonyl iron. Seven days after the STZ injection, glucose levels were measured, and only animals with glucose levels above 250 mg/dl remained in the experimental group. The total experimental time was 45 days.

Sample preparation. On experimental day 45, fasting hamsters were anesthetized and euthanized by an intraperitoneal injection of pentobarbital (Sigma, 60 mg/kg body weight). Blood samples were collected and centrifuged in 1.5 ml tubes for determination of serum components. Liver and pancreas were removed, weighed and stored either in liquid nitrogen or buffered formaldehyde for biochemical and histopathological analysis, respectively.

Assay methods. The concentration of serum iron was determined by spectrophotometric analysis using Labtest kit # 38 (Minas Gerais, Brazil) with a standard iron solution (500 μg/dl). Liver samples, 100 mg, were digested in 2 ml of nitric acid at 100°C. Excess acid was evaporated and iron levels were quantified by colorimetric analysis according to the Association of Official Analytical Chemistry (AOAC). The orthophenanthroline assay with an iron solution of 500 μg/dl as an external iron standard. Labtest kits # 53, 42, 99 and 19 were used to measure the activities of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum concentration of total proteins and albumin, respectively. Glucose and fructosamine concentrations and amylase activity were determined using Labtest kits # 84, 97 and 25 respectively. Triglycerides and total cholesterol concentrations were measured using Labtest kits # 59 and 60 with glycerol or cholesterol as standards, respectively. Following low density lipoprotein (LDL) and very low density lipoprotein (VLDL) precipitation with phosphotungstic acid and MgCl₂, high density lipoprotein (HDL) cholesterol was measured in the supernatant using Labtest kit # 3. The remaining cholesterol fractions were calculated based on the difference between total and HDL cholesterol.

Histopathological evaluation. Liver and pancreas fragments not exceeding 4 mm in diameter were fixed in 10% formaldehyde solution and then dehydrated, diaphanized and embedded in paraffin. Paraffin sections of approximately 4 μm were obtained by sectioning embedded fragments on a rotary microtome. Sections were mounted on glass slides previously cleaned and degressed. Slides were stained with Hematoxylin and Eosin for visualization of histological changes and with Perls’ technique for determination of tissue iron pools. Digital morphometric analysis, conducted for determination of the average size and area of pancreatic islets as well as quantification of tissue iron pools, were done using a Leica DM5000 optical microscope with the Leica analysis software Qwin Plus.

Quantitative real-time RT-PCR assay. Trizol RNA extraction of liver, approximately 50 mg, was done using RNAgent Promega-Total RNA Isolation System (Madison) according to the manufacturer’s recommendations. Total RNA concentration and purity was determined by spectrophotometric analysis at 260 and 280 nm on a NanoVue spectrophotometer (GE Healthcare, United Kingdom). cDNA was synthesized from total RNA using GeneAmp® RNA PCR (Applied Biosystems, Foster City). Briefly, cDNA was prepared in a 20 μl reaction using MultiScribe™ (50 U/μl) Reverse Transcriptase and Oligo d(T)₁₅ primers (Applied Biosystems). Gene expression was analyzed using SYBR Green PCR Master Mix (Applied Biosystems). PPAR-α gene expression was normalized to that of β-actin. Primer sequences were as follows: F-TGTCGAATATGTGGGGACAA and R-AAACGCGATTGCATTGTGTA for PPAR-α and F-ACTGGCATATTG-ATGGACTC and R-GTGGTTGGTGAAGCTGTAGCC for β-actin. cDNA was amplified at 95–60°C for 40 cycles in an ABI 7300 Real-Time PCR instrument (Applied Biosystems). All samples were analyzed in triplicate. Measurement of relative PPAR distribution was done for each animal. Cycle Threshold values (ACT) were obtained by subtracting β-actin CT values from the respective PPAR CT values.

Activity of enzyme and antioxidant compound. Total glutathione concentration (GSH and GSSH) in liver homogenates was determined using Sigma Kit CS0260 (EUA). This assay utilizes a kinetic method to measure glutathione based on the reduction of DTNB (5,5'-dithio-bis-(2-nitrobenzoic) acid) to TNB, which can be spectrophotometrically determined at 412 nm. Sigma G4251 reduced glutathione was used as a standard. Catalase activity was determined according to Aebi. Briefly, 10 μl of tissue homogenate supernatant were added to a cuvette containing 2 ml of 50 mmol/l phosphate buffer (pH 7.2). The reaction was initiated by the addition of 1 ml of substrate (30 mM H₂O₂ in phosphate buffer). The rate of H₂O₂ decomposition was measured spectrophotometrically in 1-min intervals at 240 nm against a blank containing phosphate buffer instead of substrate. The decomposition of hydrogen peroxide was calculated using the molar extinction coefficient 39.41 L.mol⁻¹.cm⁻³. One U of catalase is equivalent to the hydrolysis of 1 μmol of H₂O₂ per minute.

Protein oxidation analysis. Carbonyl protein was measured by using the modified method of Levine. In brief, 0.5 ml of supernatant was placed in two tubes. Then 0.5 ml of 10 mM 2,4-dinitrophenylhydrazine (DNPH) in 2.5 M HCl was added to one of the tubes, while 0.5 ml of HCl (2.5 mM) was added to the other.
Results

Iron status, biochemical indicators of hepatic function and body liver weights. The concentration of iron in the serum was twice as high in animals from the CI group as compared to animals in the C group (Table 1). This result is in contrast to animals in group DI, whose serum iron concentrations were comparable to those of animals in group C. Surprisingly, animals of group D had higher concentrations of serum iron than those in group C. Iron levels in the liver were also analyzed, and, in this case, we found that animals whose diet was supplemented with carbonyl iron, namely groups CI and DI, had iron levels equivalent to 6- and 4.4-fold those of group C, respectively. We found that animals in group DI, whose serum iron concentrations were 2.89 times higher, showed 2.6 times higher than those in group C, whereas fructosamine levels were 1.8 times higher in group D than in group C. Amylase activity, on the other hand, was decreased by 5.1% in group D as compared to group C. The administration of excess iron potentiated the changes in the glycemic profile caused by diabetes. Animals of group DI had fructosamine levels 3.56 times higher than those in group C. Amylase activity was further decreased by 5% in group DI. The concentration of serum triglycerides was higher in group DI than in groups D and CI, with no significant difference noted between these and group C. Hamsters of group DI showed decreased total serum cholesterol as compared to the other groups. Data analysis of HDL cholesterol concentration showed that this was also decreased in animals of groups DI and D. The later showed an increase in the other cholesterol fractions that was not seen in group DI.

Histological analysis. Histological analysis showed that, overall, the liver of animals in group C was normal. There were some ballooned hepatocytes that had large and clear cytoplasm (Fig. 1A), indicating the presence of a hydropic degenerative

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>Control + Iron</th>
<th>Diabetes</th>
<th>Diabetes + Iron</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Iron μmol/l</td>
<td>36.45 ± 5.34&lt;sup&gt;a&lt;/sup&gt;</td>
<td>37.63 ± 8.98&lt;sup&gt;b&lt;/sup&gt;</td>
<td>52.42 ± 5.57&lt;sup&gt;b&lt;/sup&gt;</td>
<td>40.06 ± 7.68&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Liver Iron μmol</td>
<td>0.69 ± 0.24&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.38 ± 2.28&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.83 ± 0.11&lt;sup&gt;c&lt;/sup&gt;</td>
<td>3.09 ± 2.67&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>ALT U/ml</td>
<td>44.55 ± 10.78&lt;sup&gt;b&lt;/sup&gt;</td>
<td>61.16 ± 13.87&lt;sup&gt;b&lt;/sup&gt;</td>
<td>115.12 ± 58.39&lt;sup&gt;b&lt;/sup&gt;</td>
<td>70.75 ± 21.85&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>AST U/ml</td>
<td>47.66 ± 10.78&lt;sup&gt;b&lt;/sup&gt;</td>
<td>55.37 ± 13.87&lt;sup&gt;b&lt;/sup&gt;</td>
<td>49.29 ± 13.87&lt;sup&gt;b&lt;/sup&gt;</td>
<td>64.86 ± 7.55&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Albumin μmol/l</td>
<td>30.22 ± 4.63&lt;sup&gt;a&lt;/sup&gt;</td>
<td>35.18 ± 18.39&lt;sup&gt;b&lt;/sup&gt;</td>
<td>298.09 ± 6.95&lt;sup&gt;b&lt;/sup&gt;</td>
<td>292.07 ± 18.17&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Total Protein g/l</td>
<td>30.13 ± 3.13&lt;sup&gt;b&lt;/sup&gt;</td>
<td>31.33 ± 2.31&lt;sup&gt;b&lt;/sup&gt;</td>
<td>26.32 ± 2.09&lt;sup&gt;b&lt;/sup&gt;</td>
<td>25.51 ± 1.25&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Glucose mmol/l</td>
<td>7.06 ± 1.51&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.15 ± 0.99&lt;sup&gt;b&lt;/sup&gt;</td>
<td>18.44 ± 0.99&lt;sup&gt;b&lt;/sup&gt;</td>
<td>25.15 ± 1.96&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fructosamine μmol/l</td>
<td>9.35 ± 1.71&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12.72 ± 2.3&lt;sup&gt;c&lt;/sup&gt;</td>
<td>16.86 ± 1.9&lt;sup&gt;c&lt;/sup&gt;</td>
<td>14.34 ± 2.6&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Amylase U/dl</td>
<td>770.59 ± 5.67&lt;sup&gt;c&lt;/sup&gt;</td>
<td>735.95 ± 12.13&lt;sup&gt;c&lt;/sup&gt;</td>
<td>731.09 ± 7.37&lt;sup&gt;c&lt;/sup&gt;</td>
<td>726.47 ± 5.37&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cholesterol mmol/l</td>
<td>3.03 ± 0.44&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.49 ± 0.59&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.89 ± 0.64&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.91 ± 0.33&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Triglycerides mmol/l</td>
<td>2.49 ± 0.99&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.89 ± 0.62&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.89 ± 0.35&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.93 ± 0.93&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HDL mmol/l</td>
<td>1.57 ± 0.22&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.84 ± 0.38&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.93 ± 0.11&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.88 ± 0.11&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Other Fractions mmol/l</td>
<td>1.46 ± 0.38&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.64 ± 0.58&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.04 ± 0.36&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.03 ± 0.31&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; HDL, high-density lipoprotein; Values are shown as the mean ± standard deviation (n = 8). Data were analyzed by bivariate ANOVA analysis. When one of the factors was significant (p<0.05) univariate analysis with Tukey post test was performed to determine specific differences between means. Statistical differences are shown by different superscript letters.
process. These are generally associated with inflammatory processes with a predominance of mononuclear cells, mainly macrophages. This inflammatory process occurred in the presence of normal levels of iron stores. Animals of the CI group showed a moderate presence of ballooned hepatic cells, which were diffuse throughout the parenchymal tissue. This presentation is generally associated with granulomatous inflammatory foci, and tissue iron stores were located primarily in hepatocytes and Kupffer cells (Fig. 1 C and E).

The most important lesion found in animals of groups D and DI was the presence of numerous hepatic cells with multiple intracytoplasmic vesicles presenting as a negative image on HE staining, which is a morphologic indication of multilocus steatosis. In animals of group D, steatosis was mild, located in hepatic portal regions (Fig. 1B) and was associated with the presence of small inflammatory foci without the presence of tissue iron stores. In animals of the DI group, the steatosis was also mild, but in this case, it was diffused throughout all areas of the liver and was associated with small inflammatory foci and tissue iron pools (Fig. 1 D and F). Histological analysis of Perls for C and D groups showed no iron deposits.

Pancreatic analysis showed that animals in group CI had pancreatic islets one fold higher than animals in group C. However, animals in both groups D and DI showed average size of pancreatic islets equal as compared to those in group C (Fig. 2). Total percentage of the pancreatic area occupied by islets was 8.23% for group C and 10.24% for group CI, both of which were significantly higher than those observed for groups D and DI, in which the percentage was 2.98% and 4.82%, respectively (Fig. 2). Histological studies showed no changes in cell profiles in any of the pancreatic regions. Furthermore, no tissue iron pools in all groups analyzed was seen.

**Antioxidant status.** Results of these analyses are shown in Table 2. We found that diabetes reduced the antioxidant status in the liver, as it caused a decrease of 8.5% and 33% in hepatic glutathione and catalase activities, respectively. However, an interaction of excess iron with diabetes, led to an increase in this antioxidant status as seen by the activities of both glutathione and catalase in the liver.

**Liver carbonyl protein.** As shown in Table 2, levels of carbonyl protein in the liver of animals from group D were found to be 41% higher than those in group C. Animals in group DI had carbonyl protein levels equal to those in group C.

**PPAR-α/β-actin relative levels in the liver.** Fig. 3 shows qPCR analysis of the expression of PPAR-α in the liver of diabetic hamsters. Animals in the liver of those whose diets were supplemented with excess iron. PPAR-α mRNA levels were significantly lower (85%) in group D as compared to group C. However, excess iron did not alter the expression of PPAR-α mRNA.

**Discussion**

Iron treatment increased serum and tissue iron levels. Surprisingly, although both control and diabetics groups have received the same treatment with carbonyl iron, apparently, animals that received both treatments presented an alteration in iron homeostasis, leading to a lower concentration of iron in serum and liver. It is known that the amount of plasma iron is determined by a regulated liberation of iron from most cells of the body. Macrophages, intestinal enterocytes, and hepatocytes have a particularly important role in this process, and this cellular efflux is modulated by liver hepcidin. Fernandez Real et al. verified that hepcidin levels increased significantly in patients with type 2 diabetes. Our data suggest that the interaction between iron supplementation and diabetes triggers changes in iron homeostasis, contributing to a lower absorption, resulting in lower iron levels in serum and liver. This effect can also be attributed to insulin since in vitro data suggest that it is capable of redistributing the cellular pool of transferring receptors, increasing the proportion of the cell surface, leading to increased cellular iron uptake in adipose tissue and the liver. In our experimental model STZ destroys the beta cells, promoting insulin deficiency, which may have caused a smaller deposit of iron in the DI group as compared to CI. Our data on glycemic and lipids profile, besides the histological aspect of the pancreas showed a detrimental interaction between diabetes and iron. These data support those from epidemiological studies which show a correlation between increased iron stores and diabetes. On the other hand, the histological aspect of the liver in group DI followed the same profile of D group and the liver antioxidant levels were increased as compared to group D. Our results show the different tissue vulnerability to ferrodiabetes interaction. Damage through reactive oxygen species is determined not only by the generation of free oxygen radicals but also by the antioxidant defense status of the cell. This is why different organs can exhibit considerable differences in their susceptibility towards cytotoxic damage. Lenzen et al. showed that in pancreatic islets very low levels of gene expression of all antioxidant enzymes are observe compared to liver. Further, seem that the higher expression of PPAR-α and lower oxidative stress played an important role in hepatic integrity. The histological data obtained here indicate that our model of iron supplementation caused less damage to the liver, as we did not see any fibrosis,
thereby suggesting preservation of the metabolic functions, what was further supported by total protein and albumin concentrations. When we consider the activity of ALT, a marker of liver function, the DI group showed intermediate levels between C and D. This corroborates with data of oxidative stress and PPAR-α expression in the liver, indicating that the interaction of iron with diabetes reversed damage caused by the disease. As for AST activity, it was shown to be increased in the animals that received iron supplementation, whether they were diabetic or not. An increase in the concentration of AST may reflect damage to other organs such as muscle, since it is not distributed in various tissues. The data of activity of these enzymes also allow us to suppose that the interaction between iron and diabetes promoted different effects on the different tissues, possibly because the susceptibility of these tissues to oxidative stress is different.

In the present study we have found differential expression of liver PPAR-α among diabetic and iron-induced diabetic hamsters. PPAR-α was expressed at relatively lower levels in the diabetic animals. Previous studies have shown that the expression of PPAR-α can be regulated by diabetes. Marcill et al. showed that oxidative stress decreases PPAR-α expression in macrophages of diabetic animals. Furthermore, Wang et al. investigated the expression of PPAR-α in aorta, renal cortex and retina of diabetic rats and found it to be decreased in all studied tissues, besides Li et al. having shown that type 2 diabetic hamsters also had decreased expression of this mRNA in the liver. It has been previously indicated that oxidative stress increases during diabetes and contributes to down-regulation of PPAR-α in atrial myocytes both in vitro and in vivo. In the present study, diabetes significantly increased oxidative stress as evaluated by increasing carbonyl protein and decreasing glutathione levels and catalase activity, but was attenuated in iron-treated diabetic hamsters. The effectiveness of iron-diabetes to attenuate oxidative stress might be due to the greater induction of NF-E2-related factor 2 (Nrf2) target genes. This activation induces the production of antioxidant compounds and enzymes. Tanaka et al. have demonstrated that coordinated induction of Nrf2 target genes protects against iron nitritotriacetate (FeNTA)-induced nephro-

### Table 2. Hamster antioxidant and carbonyl protein levels

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control</th>
<th>Control + Iron</th>
<th>Diabetes</th>
<th>Diabetes + Iron</th>
<th>ANOVA (p values)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver glutathione nmoles/ml</td>
<td>40.43 ± 4.81&lt;sup&gt;a&lt;/sup&gt;</td>
<td>40.12 ± 1.61&lt;sup&gt;a&lt;/sup&gt;</td>
<td>34.77 ± 3.06&lt;sup&gt;b&lt;/sup&gt;</td>
<td>40.01 ± 5.47&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.146 0.0383 0.097</td>
</tr>
<tr>
<td>Liver catalase μmol/mg protein</td>
<td>18.30 ± 3.19&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16.75 ± 3.274&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.16 ± 1.34&lt;sup&gt;b&lt;/sup&gt;</td>
<td>17.67 ± 2.36&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.104 0.01 0.002</td>
</tr>
<tr>
<td>Liver carbonyl protein nmol/mg protein</td>
<td>2.25 ± 1.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.24 ± 1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.74 ± 0.76&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.18 ± 0.63&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.685 0.108 0.0445</td>
</tr>
</tbody>
</table>

<sup>a</sup> Values are shown as the mean ± standard deviation (n = 8). Data were analyzed by bivariate ANOVA analysis. When one of the factors was significant (p<0.05) univariate analysis with Tukey post test was performed to determine specific differences between means. Statistical differences are shown by different superscript letters.
Fig. 3. Levels of relative PPAR-α/β-actin expression in the liver of hamsters offered the standard diet (C), the C diet supplemented with carbonyl iron (CI) and diabetic hamsters offered the standard diet (D) and diabetic hamsters offered the C diet supplemented with carbonyl iron (DI)*.

* Values are mean ± standard deviation (n = 4). Data were analyzed by the Kruskal-Wallis test. Statistical differences are shown by different letters.

Toxicity. Our results concerning antioxidants suggest that the interaction between diabetes and iron alters the redox balance and accounts for increased antioxidant levels, thus contributing to a higher expression of PPAR-α mRNA.

Reduced expressions of PPAR-α have been associated with lipid accumulation. Increased concentration of triglycerides and reduced HDL levels are key characteristics of dyslipidemia in diabetes. Previous studies have shown that excess iron can increase the concentration of triglycerides in the circulation. Although increases in LDL-cholesterol and triglycerides are common in diabetic dyslipidemia, we did not observe changes in the levels of these metabolites in our diabetes model, probably due to the fact that in STZ-induced diabetes there is a reduction in insulin secretion. When iron was associated with diabetes, lower cholesterol and higher triglyceride levels were observed. Our data suggest that the alterations in serum lipid homeostasis in group DI are independent of PPAR-α expression because the levels of expression of this mRNA were comparable to the group C and higher than the D groups; this was possibly due to the strong influence of insulin deficiency. HMG-CoA reductase, a key enzyme in the synthesis of cholesterol, has its activity stimulated by this hormone, thus lower insulin levels would lead to less cholesterol synthesis, justifying our data for cholesterol. Lower activity of lipoprotein lipase can contribute to higher levels of triglycerides because this enzyme is essential to the removal of triglycerides from the blood stream and further degradation and it is attenuated in insulin deprivation. Furthermore, although there is no significant difference between body weight of animals in groups D and DI, there is a tendency of group DI to have lower body weight than group D. When we analyzed glucose levels of these two groups it was observed that they were higher in the DI group, suggesting a reduced production of insulin, which can lead to increased lipolysis and proteolysis in this group, leading to greater weight loss in the DI animals as compared to the DI group.

Our data support those from epidemiological studies which show a correlation between increased iron pools and diabetes. It has been reported in clinical studies that increased iron levels in serum and specific tissues may increase the incidence of type 2 diabetes and gestational diabetes. Iron depletion has been demonstrated to be beneficial in coronary artery responses, endothelial dysfunction, insulin secretion, insulin action, and metabolic control in type 2 diabetes. Our results show that iron supplemented in diabetes type I model increased serum concentrations of glucose. The interaction between iron and diabetes promoted different effects on the liver and pancreas, possibly because the susceptibility of these tissues to oxidative stress is different. Besides, for the first time, we have shown that PPAR-α expression is differentially expressed in diabetic and iron supplemented-diabetic hamsters livers.

Acknowledgments

This study was supported by the Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG, Minas Gerais, Brazil n CDS-APQ 01126-08) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil n 475823/2007-9).

We thank Dr. Maria Terezinha Bahia (Chagas’ Disease Laboratory, Federal University of Ouro Preto) for the use of the real time PCR ABI 7300 equipment (Applied Biosystems). We are grateful to Rinaldo Cardoso dos Santos for suggestions and careful review of the manuscript.

Abbreviations

ALT alanine aminotransferase
ANOVA analysis of variance
AST aspartate aminotransferase
AOAC Association of Official Analytical Chemists
CI Control iron group
CT Cycle Threshold
DNPH 2,4-Dinitrophenylhydrazine
DTNB 5,5-dithio-bis-(2-nitrobenzoic) acid
DI Diabetes iron group
FeNTA iron-nitrilotriacetate
HDL high density lipoprotein
LDL low density lipoprotein
MDA malondialdehyde
Nrf2 NF-E2-related factor-2
PPAR Peroxisome proliferator-activated receptor
ROS Reactive oxygen species
STZ streptozotocin
TCA trichloroacetic acid
TNB 2-nitro-5-thiobenzoic acid
VLDL very low density lipoprotein

References


M. Silva et al.
108


